Bone densitometry company Hologic introduced two new digital general radiography systems this month at the RSNA show. Epex and Radex are based on DirectRay solid-state electronic and semiconductor technologies to capture x-rays. Epex is a high-end unit,
Bone densitometry company Hologic introduced two new digital general radiography systems this month at the RSNA show. Epex and Radex are based on DirectRay solid-state electronic and semiconductor technologies to capture x-rays. Epex is a high-end unit, while Radex is a simpler system designed for the outpatient market. Both units will be installed in clinical facilities during the second quarter of 2000.
The two new units round out the Bedford, MA, companys product line, which also includes its DR1000C digital chest system and DR1000 general radiography system. DR1000C units have been installed in five European countries, as well as at sites in Canada and the U.S., and Hologic made its first clinical installations of DR1000 in November.
In other Hologic news, the firm has established a new organizational structure for bringing its systems to market: Hologic will design, market, and service its radiographic products, while its subsidiary, Direct Radiography Corp. (DRC), will be responsible for designing, manufacturing, and servicing DirectRay detectors. DRC will market the detectors as fully integrated Hologic radiographic systems, as a digital image capture upgrade for existing x-ray equipment sold through distributors, and as a component for OEMs.
Stay at the forefront of radiology with the Diagnostic Imaging newsletter, delivering the latest news, clinical insights, and imaging advancements for today’s radiologists.
Study Shows Enhanced Diagnosis of Coronary Artery Stenosis with Photon-Counting CTA
July 10th 2025In a new study comparing standard resolution and ultra-high resolution modes for patients undergoing coronary CTA with photon-counting detector CT, researchers found that segment-level sensitivity and accuracy rates for diagnosing coronary artery stenosis were consistently > 89.6 percent.
FDA Expands Approval of MRI-Guided Ultrasound Treatment for Patients with Parkinson’s Disease
July 9th 2025For patients with advanced Parkinson’s disease, the expanded FDA approval of the Exablate Neuro platform allows for the use of MRI-guided focused ultrasound in performing staged bilateral pallidothalamic tractotomy.